Search Results

You are looking at 11 - 20 of 47 items for :

  • "Interferon-α" x
  • Refine by Access: All x
Clear All
Full access

Point: Intraperitoneal Chemotherapy in the Management of Ovarian Cancer

Maurie Markman

mitoxantrone in the management of refractory ovarian carcinoma . J Clin Oncol 1990 ; 8 : 146 – 150 . 25 Berek JS Markman M Stonebraker B . Intraperitoneal interferon-α in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study

Full access

Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management

Prithviraj Bose and Srdan Verstovsek

molecular responses, have been reported with the use of pegylated interferon-α-2a in both PV and ET. 38 , 39 One study in 40 patients with PV reported a CHR rate of 94.6% and a decrease in the percentage of mutated JAK2 in 89.6% of patients, with

Full access

Interferons as the First Choice of Cytoreduction in Essential Thrombocythemia and Polycythemia Vera

Joan How and Gabriela Hobbs

. Mullally A , Bruedigam C , Poveromo L , Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera . Blood 2013 ; 121 : 3692 – 3702 . 10.1182/blood-2012-05-432989 4

Full access

Perioperative Intravesical Chemotherapy in Non–Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

Michael R. Abern, Richmond A. Owusu, Mark R. Anderson, Edward N. Rampersaud, and Brant A. Inman

). Cumulative meta-analysis showed that the TUR+IVC treatment effect has been stable over time and not subject to temporal changes ( Figure 3 ). Study Drug, Dose, and Dwell Time When trial outcomes were analyzed by drug, gemcitabine and interferon α-2b

Full access

Part I: The Role of Maintenance Therapy in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Philip L. McCarthy

, well-tolerated with manageable toxicities, simple to administer, and feasible for long-term administration. Older agents, including lower doses of melphalan, interferon-α, and glucocorticoids, have been used for maintenance after primary induction

Full access

Ten Years of Progress in Melanoma

John A. Thompson

-dose interferon α-2b (HD IFN α-2b) was approved by the FDA in 1995 for adjuvant therapy of resected stage IIB and III melanoma based on the results of ECOG E1684. Results of E1690 were presented in 2000 and confirmed an improvement in relapse-free survival (RFS

Full access

NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia

Neil P. Shah

combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients . Leukemia 2016 ; 30 : 1853 – 1860 . 27133821 10.1038/leu.2016.121 10. Richter J , Söderlund S , Lübking A , Musculoskeletal

Full access

Response Monitoring, Tolerability, and Effectiveness of Imatinib Treatment for Chronic Myeloid Leukemia in a Retrospective Research Database

David D. Stenehjem, Frederick Albright, Kuan-Ling Kuo, Karina Raimundo, Hillevi Bauer, Paul J. Shami, Michael W. Deininger, Lei Chen, and Diana I. Brixner

Imatinib became the front-line treatment for patients with chronic-phase chronic myelogenous leukemia (CP-CML) based on results from the International Randomized Study of Interferon and STI571 (IRIS), which compared imatinib versus interferon-α

Full access

Psychological Symptoms Among Patients With BCR-ABL–Negative Myeloproliferative Neoplasms

Daniel C. McFarland, Heather Polizzi, John Mascarenhas, Marina Kremyanskaya, Jimmie Holland, and Ronald Hoffman

cytokines are also elevated in the setting of depression and contribute to the cytokine hypothesis of depression that has been proposed based on “sickness behavior” models that can be induced with the administration of interferon-α therapy. 8 – 11

Full access

Kidney Cancer, Version 2.2014

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Kanishka Sircar, Brad Somer, Jue Wang, Richard B. Wilder, Mary A. Dwyer, and Rashmi Kumar

histologies. 7 , 8 The median overall survival (OS) was 11.6 months with temsirolimus, compared with 4.3 months with interferon-α, in patients with non-clear cell RCC (predominantly papillary RCC). 8 This is the only reported phase III trial that included